<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972673</url>
  </required_header>
  <id_info>
    <org_study_id>112018</org_study_id>
    <nct_id>NCT00972673</nct_id>
  </id_info>
  <brief_title>A Study of GW685698X in Healthy Japanese Male Subjects</brief_title>
  <official_title>Phase I Study of GW685698X-A Randomized, Double Blind, Placebo Controlled, Parallel-group, Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Dose From a Novel Dry Powder Device in Healthy Japanese Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, placebo controlled, parallel-group, repeat dose study to
      investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose
      from a novel dry powder device in healthy Japanese male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2008</start_date>
  <completion_date type="Actual">December 19, 2008</completion_date>
  <primary_completion_date type="Actual">December 19, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety: adverse events, vital sign, ECGs, and clinical laboratory test</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>PK： Cmax, tmax and AUC(0-t)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>PD: serum cortisol</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Arm 1 subjects will receive 200, 400 or 800 microgram of powdered inhalation of GW685698X once daily for 7 days from Day 5 to Day 11.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Arm 2 subjects will receive Placebo powdered inhalation once daily for 7 days from Day 5 to Day 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>comparator</description>
    <arm_group_label>arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW685698X</intervention_name>
    <description>Inhaled steroid</description>
    <arm_group_label>arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese healthy male subjects aged between 20 and 64 years of age inclusive. Healthy
             subjects are defined as individuals who are free from clinically significant illness
             or disease as determined by their medical history, physical examination, laboratory
             studies, and other tests.

          -  Body weight ≥ 50kg and BMI within the range 18.5-25.0kg/m2 inclusive.

          -  Non-smokers (never smoked or not smoking for &gt;6 months with &lt;10 pack years history
             (Pack years = (cigarettes per day smoked/20) x number of years smoked))

          -  Clinical laboratory tests data obtained at screening meet the following:

        AST(GOT), ALT(GPT), total-bilirubin: below the upper limit of the normal ranges

          -  Normal 12-lead EGC finding at screening; QTc(B) interval &lt;450msec

          -  Normal spirometry (FEV1 ≥ 80% of predicted, FEV1/FVC ≥ 70%).

          -  Rapid ACTH with normal range at the screening.

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  Capable of using the novel dry powder inhaler.

        Exclusion Criteria:

          -  The subject has any clinically relevant abnormality on medical examination, vital
             sign, clinical laboratory test or medical history at screening in the medical opinion
             of the investigator or the subject has a medical history that is not considered as
             eligible for inclusion in this study by the investigator.

          -  The subject has an allergy for any drug or idiosyncrasy

          -  The subject has an allergy for any drug hypersensitivity to milk protein or the
             excipients lactose monohydrate and magnesium stearate.

          -  T he subject is currently participating in another clinical study or post-marketing
             study in which the subject is or will be exposed to an investigational or a
             non-investigational drug or device.

          -  The subject has participated in a clinical study with an investigational or a
             non-investigational drug or device during the previous 4 months.

          -  The subject has a history or current conditions of drug abuse or alcoholism.

          -  History of regular alcohol consumption exceeding on average, 14 drinks/week (1 drink =
             5 ounces (150mL) of wine or 350mL of beer or 1.5 ounces (45mL) of 80 proof distilled
             spirits) within 6 month of screening.

          -  The subject is positive for urine drug at screening.

          -  Use of prescription or non-prescription drugs, including CYP3A/PGP inhibitor,
             vitamins, herbal and dietary supplements (including St John'sWort) within 14 days
             prior to the first dose of study medication.

          -  The subject has a known allergy or hypersensitivity to corticosteroids.

          -  The subject has a known allergy or hypersensitivity to synthetic ACTH

          -  The subject has a history of asthma in childhood or respiratory disorder.

          -  The subject is a permanent (or occasional during the study) night-shift worker*.

             * Permanent night shift worker defines as the person who has been continuing life that
             gets up after 12:00 day time and eats supper after 0:00 midnight for seven days or
             more usually.

          -  The subject is positive for syphilis, HBs antigen, HCV antibody, HIV antibody, HTLV-1
             antibody.

          -  The subject has donated a unit of blood &quot;&gt;400mL&quot; within the previous 4 months or
             &quot;&gt;200mL&quot; within the previous 1 month.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-0081</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/112018?search=study&amp;search_terms=112018#rs</url>
    <description>Results for study 112018 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Nakahara N, Wakamatsu A, Kempsford R, Allen A, Yamada M, Nohda S, Hirama T. The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. Int J Clin Pharmacol Ther. 2013 Aug;51(8):660-71. doi: 10.5414/CP201822.</citation>
    <PMID>23735179</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2009</study_first_submitted>
  <study_first_submitted_qc>September 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2009</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>112018</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112018</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112018</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112018</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

